Land: New Zealand
Sprog: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Etoposide 20 mg/mL
REX Medical Ltd
Etoposide 20 mg/mL
20 mg/mL
Solution for injection
Active: Etoposide 20 mg/mL Excipient: Benzyl alcohol Citric acid Ethanol Macrogol 300 Polysorbate 80
Vial, glass, Type I with bromobutyl rubber stopper., 5 mL
Prescription
Prescription
Cipla Ltd
Small-cell lung cancer: Etoposide Solution for Injection is indicated for the first-line treatment of small cell lung cancer with additional chemotherapeutic agents.
Package - Contents - Shelf Life: Vial, glass, Type I with bromobutyl rubber stopper. - 5 mL - 36 months from date of manufacture stored at or below 25°C protect from light
2006-06-28
1 NEW ZEALAND DATASHEET 1 PRODUCT NAME Etoposide Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Etoposide 100 mg/5 ml Solution for Injection 3 PHARMACEUTICAL FORM Etoposide Injection is a sterile solution that is clear and colourless to pale yellow with a pH of 3–4. Etoposide Injection is available in a 5 ml single-use clear glass vial containing 100 mg etoposide. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications SMALL-CELL LUNG CANCER: Etoposide Solution for Injection is indicated for the first-line treatment of small-cell lung cancer with additional chemotherapeutic agents. HODGKIN’S DISEASE MALIGNANT (NON-HODGKIN’S) LYMPHOMAS, PARTICULARLY OF THE HISTIOCYTIC VARIETY ACUTE NON-LYMPHOCYTIC LEUKAEMIA TESTICULAR TUMOURS: Etoposide Solution for Injection is indicated both as the first-line combination regimens and for the treatment of refractory testicular tumours. 4.2 Dose and method of administration Etoposide Solution for Injection must be diluted immediately prior to administration with either 5% Dextrose Injection or 0.9% Sodium Chloride Injection to give a solution concentration of 0.2 to 0.4 mg/ml of Etoposide (see Preparation for Administration). _ _ _DOSAGE IN ADULTS _ Etoposide Solution for Injection is to be administered slowly at a dosage of 50–100 mg/m 2 on days 1 to 5 every 3 or 4 weeks or 100 mg/m 2 on days 1, 3 and 5 every 3 or 4 weeks. Total dosage must be adapted based upon the myelosuppressive effects of combinations with other medicines and or the effects of previous chemotherapy or X-ray therapy which possibly could have compromised the reserves of the bone marrow. Most patients undergo three or four treatment cycles with Etoposide Solution for Injection. Treatment cycles may be repeated and dosage adjusted (increased or decreased) depending on the individual patient’s bone marrow reserve and tumour reserve. The optimum use of Etoposide Solution for Injection is in combination with other chemotherapeutic agents. _ _ _DOSAGE IN ADULTS WITH RENAL IMPAIRMENT _ The dosage of Etopos Læs hele dokumentet